222 related articles for article (PubMed ID: 30706424)
1. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
Kircheis G; Lüth S
Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
3. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Butterworth RF; McPhail MJW
Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
[TBL] [Abstract][Full Text] [Related]
4. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.
Canbay A; Sowa JP
Drugs; 2019 Feb; 79(Suppl 1):39-44. PubMed ID: 30706422
[TBL] [Abstract][Full Text] [Related]
5. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S
Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303
[TBL] [Abstract][Full Text] [Related]
6. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.
Ndraha S; Hasan I; Simadibrata M
Acta Med Indones; 2011 Jan; 43(1):18-22. PubMed ID: 21339541
[TBL] [Abstract][Full Text] [Related]
7. L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic.
Butterworth RF
Drugs; 2019 Feb; 79(Suppl 1):1-3. PubMed ID: 30706421
[No Abstract] [Full Text] [Related]
8. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
Chen MF; Li RC; Chen CH; Gao XC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319
[TBL] [Abstract][Full Text] [Related]
10. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S
Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025
[TBL] [Abstract][Full Text] [Related]
11. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
Butterworth RF; Canbay A
Dig Dis; 2019; 37(1):63-68. PubMed ID: 30016770
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
[TBL] [Abstract][Full Text] [Related]
13. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.
Butterworth RF
Can J Gastroenterol Hepatol; 2019; 2019():8182195. PubMed ID: 31183339
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
[TBL] [Abstract][Full Text] [Related]
17. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure.
Rose C; Michalak A; Rao KV; Quack G; Kircheis G; Butterworth RF
Hepatology; 1999 Sep; 30(3):636-40. PubMed ID: 10462368
[TBL] [Abstract][Full Text] [Related]
18. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Bai M; Yang Z; Qi X; Fan D; Han G
J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
[TBL] [Abstract][Full Text] [Related]
19. Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy.
Ndraha S; Simadibrata M
Acta Med Indones; 2010 Jul; 42(3):158-61. PubMed ID: 20724770
[TBL] [Abstract][Full Text] [Related]
20. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
Jiang Q; Jiang XH; Zheng MH; Chen YP
J Gastroenterol Hepatol; 2009 Jan; 24(1):9-14. PubMed ID: 18823442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
